COMPASS Pathways plc is a London based clinical-stage biopharmaceutical concern focused on the development of psychedelics for the treatment of mental health conditions. The company is advancing the ...

Compass PathwaysCMPS stock surged Monday after President Donald Trump signed an executive order to ease the approval journey for psychedelic drugs. The order has two key elements. It provides a speedy ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This voice experience is generated by AI. Learn more. This ...

Nov 4 (Reuters) - Drug developer Compass Pathways (CMPS.O), opens new tab said on Tuesday it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS Pathways plc (NASDAQ:CMPS) is given fourth position on our list of most promising ...